Related Experiment Video
Updated: May 27, 2026

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
[Denosumab - a new option in the treatment of osteoporosis]
1Klinika Chorób Wewnętrznych, Endokrynologii i Diabetologii, Centralny Szpital Kliniczny MSWiA, Warszawa. edward.franek@cskmswia.pl
Insights
Denosumab, a monoclonal antibody, effectively treats osteoporosis by reducing bone resorption and increasing bone density. Clinical studies confirm its safety and efficacy across diverse patient groups, including those with kidney issues.
Area of Science:
- Immunology
- Bone Biology
- Pharmacology
Context:
- Osteoporosis treatment landscape
- Need for effective bone resorption inhibitors
- Role of RANKL pathway in bone metabolism
Purpose:
- To evaluate the efficacy and safety of denosumab for osteoporosis treatment
- To assess denosumab's impact on bone mineral density and fracture risk
- To analyze denosumab's safety profile in various patient populations
Summary:
- Denosumab is a human monoclonal antibody targeting RANK ligand (RANKL), inhibiting osteoclast formation and survival.
- This mechanism leads to decreased bone resorption, increased bone mineral density (BMD), and reduced fracture risk.
- The FREEDOM study demonstrated denosumab's efficacy and safety, comparable to placebo, across different renal function levels and cardiovascular risk profiles.
Impact:
- Provides a novel therapeutic option for osteoporosis management
- Demonstrates safety in patients with impaired renal function and high cardiovascular risk
- Contributes to understanding bone remodeling and therapeutic interventions
Abstract:
Denosumab is the international name of a human, monoclonal antibody approved for the treatment of osteoporosis. This antibody is associated with RANK ligand (RANKL), inactivating it. In consequence, the formation and survival of osteoclasts are suppressed, leading to their apoptosis. All this results in lower bone resorption, while bone mineral density (BMD) increases. Denosumab also reduces the risk of vertebral and non-vertebral fractures. This agent is similarly effective in various stages of renal function impairment; it does not impair fracture healing processes nor contribute to atherosclerosis progression in patients with high cardiovascular risks. Following an analysis of adverse effects, performed in the FREEDOM study (in which it was demonstrated that the incidence of the majority of adverse effects observed in the course of denosumab use was similar to that in the placebo group), its safety for patients can definitely be confirmed.
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
